Drug or intervention
Liraglutide Clinical Trials
Studies that test Liraglutide, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 35Obesity & Overweight
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity
This observational study will compare weight loss over two years in adults receiving GLP-1 receptor agonist medications with weight loss in adults who previously underwent laparoscopic sleeve gastrectomy, an operation that…
- Trial name
- GLP-BARI-VAN (NCT07901777)
- Testing
- GLP-1 Receptor Agonist Therapy, Laparoscopic Sleeve Gastrectomy
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Yuzuncu Yil University
Endometrioid Endometrial Adenocarcinoma
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are…
- Trial name
- NCT07107334
- Testing
- Glucagon-like peptide 1 receptor agonist
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Plaque Psoriasis
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
The main aim of this study is to assess whether secukinumab treatment retention over 12 months in adult patients with moderate-to-severe plaque PsO receiving secukinumab in combination with a GLP-1 RA is non-inferior to that in…
- Trial name
- STAY SEC PsO (NCT07881783)
- Volunteers
- 3,718 people
- Sponsor
- Novartis Pharmaceuticals
Type 1 Diabetes, Type 2 Diabetes
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1.
- Trial name
- NCT06976619
- Testing
- Liraglutide Pen Injector, Saline Injections
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
This trial adopts a multicenter, randomized, double-blind, placebo-controlled parallel design. This experiment is divided into two groups: the experimental drug group and the placebo group.
- Trial name
- NCT06726577
- Testing
- TP04HN106, Saline
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Talengen Institute of Life Sciences, Shenzhen, P.R. China.
Childhood Obesity, Treatment Adherence
The Evira Study: Additional Support During Obesity Treatment
The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity.
- Trial name
- NCT06836284
- Testing
- Digi-physical treatment tool, Evira, Obesity medication with liraglutide or semaglutide
- Where
- 3 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska Institutet
Heart Failure With Preserved Ejection Fraction, Obesity
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry
GLIDE-HF is a prospective, single-center, non-interventional observational cohort registry conducted within routine outpatient heart failure care at a cardiology clinic in Poland.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Obesity, Diastolic Heart Failure, Pulmonary Hypertension
- Trial name
- GLIDE-HF (NCT07787936)
- Testing
- GLP-1 / GIP receptor agonist
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Miedziowe Centrum Zdrowia SA
Type2 Diabetes
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular…
- Trial name
- ZQL007 (NCT03883412)
- Testing
- Exercise, Liraglutide
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease
Fibrosis Lessens After Metabolic Surgery
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis
- Trial name
- FLAMES (NCT06374875)
- Testing
- Metabolic surgery, Incretin-Based Therapy
- Where
- 22 sites in United States, Brazil and 11 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Obesity & Overweight, Diabetes (DM)
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
This study examines how adults who take a GLP-1 receptor agonist medication (such as semaglutide [Ozempic, Wegovy, Rybelsus], liraglutide [Saxenda, Victoza], or tirzepatide [Mounjaro, Zepbound]) perform resistance (strength)…
- Trial name
- NCT07702461
- Testing
- Glucagon-Like Peptide-1 Agonist (GLP-1)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Ohio State University
Completed, with results posted
All 137Healthy
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal.
- Trial name
- NCT04466566
- Testing
- Saline, Exendin-9,39, Liraglutide
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Adrian Vella
Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.
- Trial name
- GRADE (NCT01794143)
- Testing
- Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide)
- Where
- 36 sites in United States
- Volunteers
- 7,850 people
- Sponsor
- GRADE Study Group
Obesity
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers.
- Trial name
- NCT05579249
- Testing
- Semaglutide, Orlistat, Phentermine/Topiramate
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Obesity
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Gastroparesis
- Trial name
- NCT06533527
- Testing
- GLP-1 medication
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Type 2 Diabetes Mellitus, Cardiovascular Diseases
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform…
- Trial name
- ON TARGET DM (NCT05073692)
- Testing
- SU, DPP4, SGLT2i
- Where
- 6 sites in United States
- Volunteers
- 241,981 people
- Sponsor
- Kaiser Permanente